Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


U.S. FDA panel backs Paladin Labs’ parasitic disease drug

2:50 pm by | 0 Comments

(Reuters) - Paladin Labs Inc's experimental drug to treat a rare parasitic disease is safe and effective enough to be approved, an advisory panel to the U.S. Food and Drug Administration said on Friday.

The drug, Impavido, is designed to treat three forms of leishmaniasis, a disease caused by a group of parasites known as Leishmania, which are spread by the bite of a female sand-fly.

The FDA is not bound to follow its advisory panel's advice but typically does so.

(Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments